Conclusion
In summary, our studies have identified a novel mechanism of the
proteasome inhibitor ixazomib induced proliferation inhibition and
apoptosis in ESCC. It is possible that this effect be mediated by
c-Myc/NOXA pathway, which might give a new insight into the anti-tumor
effect and mechanism of ixazomib in ESCC.